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higher risk of relapse, lower quality of life and higher medical costs. The adherence 
measure, persistency, refers to the duration a patient continues with therapy. This 
study aims to evaluate the non-pharmacy medical costs associated with the persistency 
of DMT’s in patients with MS. METHODS: A decision-analytic model was designed 
using persistency rates, health care resource use and costs from the published litera-
ture. The model evaluated the medical costs associated with the persistence, switching, 
and discontinuation rates of patients on interferon β1a IM, interferon β1b SC, and 
interferon β1a SC over a 2-year time horizon. Using 6-month intervals in the model, 
patients could switch to a comparator treatment, discontinue treatment, or persist/
remain on their current treatment, and would incur the non-pharmacy medical costs 
associated with each. For patients who switched treatments, the model assumed an 
equal probability of switching to the three remaining DMTs. The model also assumed 
that patients who discontinued therapy would initiate on a different therapy after one 
month of discontinuing. The overall medical costs related to persisting on treatment, 
switching treatment or discontinuing treatment were calculated for all treatment arms. 
RESULTS: Based on the results from the model, an annual per-patient medical cost 
of $7423 was observed for interferon β1a IM patients, showing a medical cost advan-
tage over patients on interferon β1b SC ($8144; 8.9%), and interferon β1a SC ($7552; 
1.7%). CONCLUSIONS: MS is a lifelong disease that requires continuous treatment. 
The results of this model show that interferon β1a IM is a cost-saving treatment for 
the medical costs associated with MS patients on disease modifying therapies.
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OBJECTIVES: Cerebrospinal ﬂ uid (CSF) leak is an unavoidable consequence of 
cranial surgery with leak rates between 0% to 25% and resulting costs ranging from 
£9,000 to £36,000. The use of polyethylene glycol (PEG) hydrogel dural sealant as 
an adjunct to sutured closure has been shown to reduce CSF leak rates as compared 
with sutures alone in cranial procedures (GR Cosgrove et al, 2007). Our hypothetical 
analysis applied the potential cost offsets of using PEG hydrogel sealant as an adjunct 
to sutured closure in 200 cranial procedures assuming CSF leak rates of 4.5% (9/200) 
(GR Cosgrove et al, 2007), compared with 10% (20/200) for ﬁ brin sealant (JA Gro-
tenhuis, 2005). METHODS: The incremental additional cost for treating CSF leaks 
using total patient costs for those with CSF leaks (£25,253) compared to those without 
CSF leaks (£10,497) was estimated at £14,756 in a Dutch study (JA Grotenhuis, 
2005). We applied this CSF leak cost to estimate potential UK hospital cost offsets 
on 200 hypothetical cranial patients using PEG hydrogel sealant (£300/treatment), 
compared with ﬁ brin sealant (£133/treatment) on all 200 patients. RESULTS: Use of 
a PEG hydrogel sealant compared with ﬁ brin sealant could potentially save £137,611 
(or £688/patient) for a hospital that performed 200 cranial surgery procedures using 
a PEG hydrogel sealant compared with using ﬁ brin sealant on all 200 procedures. 
CONCLUSIONS: This study demonstrates the potential economic advantages of using 
a PEG hydrogel sealant in cranial procedures. Future clinical direct comparative 
studies would be beneﬁ cial to conﬁ rm these ﬁ ndings and understand the possible 
economic advantages for other types of dural surgeries.
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OBJECTIVES: Epilepsy is the second most frequent neurological disease among 
adults; approximately 50–60 thousand people suffer from epilepsy in Hungary. With 
our survey we aimed to assess the cost of illness from a societal viewpoint as well as 
the quality of life associated with epilepsy in Hungary. METHODS: We conducted a 
cross-sectional questionnaire survey of 100 consecutive patients in 2 epilepsy centres 
in Hungary in collaboration with epilepsy specialists. The self-developed questionnaire 
consisted of general and disease-speciﬁ c parts to determine costs associated with 
epilepsy. Questions related to basic demographic characteristics, disease progression 
and health and social services used in the past 12 months, disease-associated non-
medical services, as well as the productivity losses of epilepsy. Two generic quality of 
life questionnaires, EQ-5D and SF-36 were also used. RESULTS: A total number of 
100 patients were assessed (60% female). The average age was 36.7 years (SD. 12.5), 
average disease duration was 15 years (SD. 12). Quality of life calculations resulted 
in mean of 0.83 (SD. 0.24) in EQ-5D, 74 (SD. 16) in VAS scale and 72.3 (SD. 20.2) 
in SF-36. Cost-of-illness calculations were carried out and direct (15%) and indirect 
costs (85%) were determined. The annual total cost of epilepsy per capita was esti-
mated to be a mean of c5179 (SD. c10,822) with the human resource method, while 
c2,552/capita/year (SD. 8659) by the friction cost method. CONCLUSIONS: Compar-
ing the 100 patients’ data with data from previous EQ-5D based population-sample 
survey shows that quality of life among people with epilepsy was lower than among 
the average Hungarian population. We found signiﬁ cant correlation (at P < 0.05) 
among all of the quality of life results and the yearly total costs (calculating both with 
human capital and friction cost methods).
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OBJECTIVES: To estimate long-term disability costs associated with tuberous sclero-
sis complex, a rare multisystem genetic disease, in Brazil. METHODS: Literature 
review for TSC long-term disability and economic burden was performed (Pubmed, 
LILACS, SciELO, CRDs). Cost estimation was limited to epilepsy (most prevalent TSC 
disorder). Cost of lost productivity in patients since epilepsy onset in childhood and 
carried in adulthood as well as caregivers’ productivity costs were estimated. The 
Human Capital Method was adopted and potential lost working years estimated till 
an active age of 65 years. It was assumed a caregiver for all ages. Average income, 
unemployment rate due to epilepsy, productivity growth and epidemiology data were 
obtained from the literature and from the Brazilian Institute of Geography and Sta-
tistics. Mean annual productivity cost per patient, total productivity cost per patient 
and the total productivity burden of TSC-related epilepsy were calculated. Costs were 
estimated in 2008 Reals and discounted at 5%. Univariate sensitivity analysis was 
conducted for epidemiology data, employment status rate, productivity growth, dis-
count rate and time horizon. RESULTS: Productivity loss was 47, 30 and 65 years 
for epilepsy onset in childhood and adulthood and caregivers, respectively. The dis-
counted and not discounted mean annual productivity cost per patient were R$1,970 
and R$11,323, total productivity cost per patient R$97,882 and R$691,150 and total 
productivity burden of TSC-related epilepsy in Brazil R$1,568,965,961 and 
R$11,078,536,271, respectively (1Euro = 3.24Reals). Results were sensitive to all the 
parameters varied in the sensitivity analysis, especially discount rate. CONCLU-
SIONS: TSC-related epilepsy is a chronic disorder associated with loss of productivity 
with a signiﬁ cant economic burden in Brazil. Although signiﬁ cant, the economic 
burden related to productivity loss is expected to be even higher since there are still 
costs deriving from absenteeism of patients and caregivers when employed looking for 
health services to be included in further analysis.
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OBJECTIVES: To determine the costs and medical resource use for the management 
of injection-site reactions (ISRs) and ﬂ u-like symptoms (FLS) associated with injectable 
disease-modifying drugs (DMDs) used to treat patients with relapsing–remitting mul-
tiple sclerosis (RRMS) in the UK. METHODS: A survey was carried out amongst 
NHS nurses to understand the management of adverse events occurring with injectable 
DMD use. Data were collected via a postal questionnaire. Responses were compiled 
for the frequency and duration of side-effects, support received and medical consulta-
tions required for adverse event management. The unit costs were derived from the 
Personal Social Services Research Unit, the Ofﬁ ce for National Statistics and the British 
National Formulary. Once all parameters and unit prices were characterised with 
conservative approaches for missing data (e.g. no GP consultation mandatory before 
antibiotics prescription), computations were processed to determine means and stan-
dard deviations (SDs). RESULTS: In total, 19 NHS nurses managing signiﬁ cant 
numbers of patients with MS for different primary care trusts participated in the 
costing survey. On average, the nurses reported that patients experienced 27 ISRs per 
year of those 33% experienced ISRs only at treatment start while 21% experienced 
ISRs continuously during the year. Seventy-four percent experienced FLS only at 
treatment start and 11% continuously. The average cost for the management of ISRs 
per year was £187 (SD £209) equivalent to an average cost of £7 per event. The 
average cost for the management of FLS per year was £166 (SD £144) equivalent to 
an average cost of £6 per event. CONCLUSIONS: This is the ﬁ rst UK study to provide 
data on the costs associated with management of ISRs and FLS occurring with inject-
able DMDs. These data, alongside prevalence estimates, enabled us to calculate the 
costs of managing adverse events associated within DMDs in an economic model.
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OBJECTIVES: Huntington’s disease (HD) is a rare neurodegenerative disease leading 
to sustained disability and poor health-related quality of life (HRQOL). As new treat-
ments are in development for HD, data on the burden of disease are required. This 
study evaluated patient health status, patient and caregiver HRQoL and costs in HD. 
METHODS: Euro-HDB is a European cross-sectional survey being conducted in eight 
European countries. Self-reported questionnaires were completed by patients and care-
givers. The patient questionnaire includes the Huntington Self-Assessment Instrument, 
a speciﬁ c tool that assesses clinical characteristics, HRQoL and health care resource 
utilization. The EQ5D questionnaire and the SF36 Survey are also included. RESULTS: 
To date, 201 patients have been enrolled in France and 124 in Italy. 
All levels of disease severity are represented. Average annual costs from societal 
